VPS35 and Parkinson disease: This finding further suggests that it was unlikely that our VPS35 D620N Tg mice developed PD neuropathy, and the literature reports that the overexpression of VPS35 D620N impairs the degradation of α-synuclein, which eventually leads to a loss of dopamine neurons [11, 24, 39, 40].